The ALS Therapy Alliance (ATA) was established in 2000 to facilitate ALS research projects and collaborations to cure ALS - a debilitating and deadly disease. This global network galvanizes a diverse group of scientists and clinicians at multiple institutions. It's unique, collaborative enterprise spans multiple laboratories, universities and disciplines around the world.
ALS (amyotrophic lateral sclerosis), also known as Lou Gehrig's Disease, is a disorder that causes progressive paralysis leading to respiratory failure and death, typically in four to six years. The disease remains fatal and there is currently no cure. The cause of this disease remains unknown.
The ATA's mission is to raise funds for - and awareness of - ALS. The organization partners with corporations, biotech and pharmaceutical firms, manufacturers and the media to raise funds and spread the word about this progressive, fatal disease through its annual Breakthrough ALS campaign. To date, ATA and its partners, including CVS/pharmacy - the largest corporate sponsor to ALS research in the U.S. - have raised more than $30 million to help find a cure for this devastating disease.
The ATA is proud to have assembled some of the most brilliant minds in the scientific and medical fields. ATA's Board of Directors consists of prestigious medical researchers from multiple institutions, including Massachusetts General Hospital, Harvard Medical School, Massachusetts Institute of Technology, Harvard College, Tufts University, Children's Hospital Boston, Brigham and Women's Hospital, Beth Israel Deaconess Hospital, Columbia University, Boston University, Brandeis University, and the University of Massachusetts Medical School. The expertise of the Board, which includes two Nobel laureates, encompasses many disciplines central to understanding, treating and ultimately curing ALS.